论文部分内容阅读
目的探讨ＬＡＫ细胞治疗慢性乙型肝炎的机制。方法应用生物学方法检测ＨＢｅＡｇ、ＨＢＶＤＮＡ均阳性慢乙肝患者治疗前后ＩＬ－２水平。结果４０例患者治疗后ＨＢｅＡｇ、ＨＢＶＤＮＡ阴转率分别为４０．４％和６８．６％。治疗前ＩＬ－２水平低于对照组（Ｐ＜０．００１），治疗后有显著提高（Ｐ＜０．００５）。依ＨＢＶ标记阴转情况分组：１组ＨＢｅＡｇ（－）、ＨＢＶＤＮＡ（－）１６例；２组ＨＢｅＡｇ（＋）、ＨＢＶＤＮＡ（－）９例；３组ＨＢｅＡｇ（＋）、ＨＢＶＤＮＡ（＋）１５例。１、２组治疗前ＩＬ－２均低于对照组（Ｐ＜０．００１），治疗后均明显提高（Ｐ＜０．００５，Ｐ＜０．０１）。３组治疗前ＩＬ－２与对照组比较无明显降低（Ｐ＞０．０５），治疗前后无显著差异（Ｐ＞０．０５），治疗后ＩＬ－２比对照组低（Ｐ＜０．０２）。结论ＩＬ－２水平明显降低的慢性乙型肝炎采用ＬＡＫ细胞回输治疗ＨＢＶ标记阴转率高。
Objective To investigate the mechanism of LAK cells in the treatment of chronic hepatitis B Methods The biological methods were used to detect the levels of IL-2 before and after treatment in patients with chronic hepatitis B who were positive for HBeAg and HBVDNA. Results After treatment, the negative conversion rates of HBeAg and HBVDNA in 40 patients were 40.4% and 68.6% respectively. The level of IL-2 before treatment was lower than that of the control group (P <0.001), and was significantly increased after treatment (P <0.005). The patients were divided into two groups according to the negative conversion of HBV: group 1 HBeAg (-) and HBVDNA (-) 16; group 2 HBeAg (+) and HBVDNA (-) 9; group 3 HBeAg (+) and HBVDNA (+) 15. The levels of IL-2 in the two groups before treatment were lower than those in the control group (P <0.001), and were significantly increased after treatment (P <0.005, P <0.01). There was no significant difference in IL-2 level between the three groups before and after treatment (P> 0.05), but there was no significant difference between before and after treatment (P> 0.05) ). Conclusion The negative conversion rate of HBV markers in patients with chronic hepatitis B with significantly decreased IL-2 levels by LAK cell transplantation is high.